ABC Transporters in Human Diseases
Mammalian ATP-binding cassette (ABC) transporters constitute a superfamily of proteins involved in many essential cellular processes. Most of these transporters are transmembrane proteins and allow the active transport of solutes, small molecules, and lipids across biological membranes. On the one h...
Saved in:
Other Authors: | |
---|---|
Format: | Electronic Book Chapter |
Language: | English |
Published: |
Basel
MDPI - Multidisciplinary Digital Publishing Institute
2022
|
Subjects: | |
Online Access: | DOAB: download the publication DOAB: description of the publication |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000naaaa2200000uu 4500 | ||
---|---|---|---|
001 | doab_20_500_12854_81041 | ||
005 | 20220506 | ||
003 | oapen | ||
006 | m o d | ||
007 | cr|mn|---annan | ||
008 | 20220506s2022 xx |||||o ||| 0|eng d | ||
020 | |a books978-3-0365-3943-0 | ||
020 | |a 9783036539447 | ||
020 | |a 9783036539430 | ||
040 | |a oapen |c oapen | ||
024 | 7 | |a 10.3390/books978-3-0365-3943-0 |c doi | |
041 | 0 | |a eng | |
042 | |a dc | ||
072 | 7 | |a GP |2 bicssc | |
072 | 7 | |a PS |2 bicssc | |
100 | 1 | |a Falguières, Thomas |4 edt | |
700 | 1 | |a Falguières, Thomas |4 oth | |
245 | 1 | 0 | |a ABC Transporters in Human Diseases |
260 | |a Basel |b MDPI - Multidisciplinary Digital Publishing Institute |c 2022 | ||
300 | |a 1 electronic resource (494 p.) | ||
336 | |a text |b txt |2 rdacontent | ||
337 | |a computer |b c |2 rdamedia | ||
338 | |a online resource |b cr |2 rdacarrier | ||
506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
520 | |a Mammalian ATP-binding cassette (ABC) transporters constitute a superfamily of proteins involved in many essential cellular processes. Most of these transporters are transmembrane proteins and allow the active transport of solutes, small molecules, and lipids across biological membranes. On the one hand, some of these transporters are involved in drug resistance (also referred to as MDR or multidrug resistance), a process known to be a major brake in most anticancer treatments, and the medical challenge is thus to specifically inhibit their function. On the other hand, molecular defects in some of these ABC transporters are correlated with several rare human diseases, the most well-documented of which being cystic fibrosis, which is caused by genetic variations in ABCC7/CFTR (cystic fibrosis transmembrane conductance regulator). In the latter case, the goal is to rescue the function of the deficient transporters using various means, such as targeted pharmacotherapies and cell or gene therapy. The aim of this Special Issue, "ABC Transporters in Human Diseases", is to present, through original articles and reviews, the state-of-the-art of our current knowledge about the role of ABC transporters in human diseases and the proposed therapeutic options based on studies ranging from cell and animal models to patients. | ||
540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
546 | |a English | ||
650 | 7 | |a Research & information: general |2 bicssc | |
650 | 7 | |a Biology, life sciences |2 bicssc | |
653 | |a ABC transporters | ||
653 | |a drug action | ||
653 | |a regulatory extension | ||
653 | |a regulatory insertion | ||
653 | |a mechanism of action | ||
653 | |a MRP1 | ||
653 | |a MRP4 | ||
653 | |a breast cancer | ||
653 | |a proliferation | ||
653 | |a migration | ||
653 | |a invasion | ||
653 | |a cAMP | ||
653 | |a ABCG2 | ||
653 | |a ABCB1 | ||
653 | |a blood-brain barrier | ||
653 | |a PET | ||
653 | |a Alzheimer's disease | ||
653 | |a beta-amyloid | ||
653 | |a tariquidar | ||
653 | |a erlotinib | ||
653 | |a ABCG5 | ||
653 | |a ABCG8 | ||
653 | |a ATP-binding cassette transporter | ||
653 | |a cholesterol | ||
653 | |a polar relay | ||
653 | |a sitosterolemia | ||
653 | |a 5' untranslated region | ||
653 | |a cis-acting elements | ||
653 | |a ABCA subfamily | ||
653 | |a bioinformatics | ||
653 | |a ABC transporter | ||
653 | |a therapy response | ||
653 | |a disease-free survival | ||
653 | |a next-generation sequencing | ||
653 | |a competitive allele-specific PCR | ||
653 | |a P-glycoprotein | ||
653 | |a amyloid-beta | ||
653 | |a neuron | ||
653 | |a SK-N-SH | ||
653 | |a gene therapy | ||
653 | |a AAV | ||
653 | |a PFIC | ||
653 | |a BSEP | ||
653 | |a ABCB11 | ||
653 | |a bile salts | ||
653 | |a intrahepatic cholestasis | ||
653 | |a chaperones | ||
653 | |a PFIC2 | ||
653 | |a BRIC | ||
653 | |a ATP-binding cassette transporter A1 (ABCA1) | ||
653 | |a cholesterol homeostasis | ||
653 | |a reverse cholesterol transport | ||
653 | |a HDL-C | ||
653 | |a dyslipidemia | ||
653 | |a type 2 diabetes | ||
653 | |a microparticles | ||
653 | |a ABCG2 genotype | ||
653 | |a clinico-genetic analysis | ||
653 | |a ethnic specificity | ||
653 | |a genetic variations | ||
653 | |a precision medicine | ||
653 | |a rare variant | ||
653 | |a Roma | ||
653 | |a serum uric acid | ||
653 | |a SUA-lowering therapy | ||
653 | |a urate transporter | ||
653 | |a bile secretion | ||
653 | |a ABCB4 | ||
653 | |a ABCC2 | ||
653 | |a ABCG5/G8 | ||
653 | |a molecular partners | ||
653 | |a phytosterol | ||
653 | |a xenosterol | ||
653 | |a atherosclerosis | ||
653 | |a gall stone | ||
653 | |a ABC | ||
653 | |a transporter | ||
653 | |a ABC (ATP-binding cassette) transporters | ||
653 | |a multidrug resistance | ||
653 | |a transport | ||
653 | |a trafficking | ||
653 | |a urate | ||
653 | |a mutations | ||
653 | |a polymorphisms | ||
653 | |a ABCC6 | ||
653 | |a TNAP | ||
653 | |a NT5E | ||
653 | |a Pseudoxanthoma elasticum (PXE) | ||
653 | |a cancer | ||
653 | |a membrane protein | ||
653 | |a functional divergence | ||
653 | |a calcification | ||
653 | |a pseudoxanthoma elasticum | ||
653 | |a generalized arterial calcification of infancy | ||
653 | |a pyrophosphate | ||
653 | |a therapies | ||
653 | |a ABCA7 | ||
653 | |a phagocytosis | ||
653 | |a Aβ peptides | ||
653 | |a yeast | ||
653 | |a multidrug transporter | ||
653 | |a anticancer | ||
653 | |a antifungal resistance | ||
653 | |a mechanism | ||
653 | |a peroxisome | ||
653 | |a adrenoleukodystrophy | ||
653 | |a fatty acids | ||
653 | |a gout | ||
653 | |a early-onset gout | ||
653 | |a hyperuricemia | ||
653 | |a uric acid | ||
653 | |a BCRP | ||
653 | |a single nucleotide polymorphism | ||
653 | |a SNP | ||
653 | |a homology modeling | ||
653 | |a substrate-binding site | ||
653 | |a cellular ATP efflux | ||
653 | |a mutagenesis | ||
653 | |a intracellular traffic | ||
653 | |a MDR3 | ||
653 | |a phosphatidylcholine | ||
653 | |a RAB GTPase | ||
653 | |a taxol | ||
653 | |a drug transport | ||
653 | |a n/a | ||
856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/5383 |7 0 |z DOAB: download the publication |
856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/81041 |7 0 |z DOAB: description of the publication |